These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29237959)

  • 41. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
    Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
    Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
    Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
    BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors.
    Valković T; Gačić V; Ivandić J; Petrov B; Dobrila-Dintinjana R; Dadić-Hero E; Načinović-Duletić A
    Turk J Haematol; 2015 Sep; 32(3):234-42. PubMed ID: 26376590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
    Voorhees PM; Orlowski RZ; Mulkey F; Watson P; Geyer S; Sanford BL; Bennett E; Chanan-Khan AA; Bloomfield CD; Larson RA
    Br J Haematol; 2015 Nov; 171(3):373-7. PubMed ID: 26202857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
    Ahn JS; Jung SH; Lee SS; Ahn SY; Yang DH; Kim YK; Kim HJ; Lee JJ
    Biomed Res Int; 2014; 2014():145843. PubMed ID: 25530955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
    Lee SE; Choi K; Han S; Lee J; Hong T; Park GJ; Yim DS; Min CK
    Anticancer Drugs; 2017 Jul; 28(6):660-668. PubMed ID: 28430745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
    Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma].
    Li X; Zhong YP; Hu Y; Zhang JJ; An N; Chen SL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):987-90. PubMed ID: 21867630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
    Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
    Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
    Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
    Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma.
    Sugiura I; Terabe S; Kinoshita T; Yamamoto K; Sawa M; Ozawa Y; Atsuta Y; Suzuki R; Shimizu K
    Int J Hematol; 2015 Oct; 102(4):434-40. PubMed ID: 26298823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
    Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
    Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.
    Wei D; Tong Y; Bai H; Cai Q; Gao Y; Wang C
    Oncotarget; 2016 Oct; 7(43):70168-70174. PubMed ID: 27659525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
    Jimenez-Zepeda VH; Duggan P; Neri P; Tay J; Bahlis NJ
    Ann Hematol; 2017 Mar; 96(3):431-439. PubMed ID: 28074255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
    Keating M; Dasanu CA
    BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27899388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.